ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
13 announcements
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
RPG Life Sciences completed its acquisition of the entire stake in Actis Generics Private Limited, making it a subsidiary of the company.
RPG Life Sciences clarified that the recent increase in its trading volume is attributable to market conditions and there is no undisclosed price-sensitive information.
RPG Life Sciences completed the slump sale of its API and intermediates business to Raghava Life Sciences Private Limited, effective September 16, 2026.
RPG Life Sciences' subsidiary, RPG Active Pharma, allotted shares to India Life Sciences Fund and Vistaject Fund for ₹243.33 crores. Post-allotment, RPG Active Pharma remains a subsidiary.
RPG Life Sciences announced a strategic reorganization of its API business into a new subsidiary, RPGAP, involving a PE partnership and two bolt-on acquisitions to drive growth.
RPG Life Sciences' subsidiary, RPG Active Pharma, will acquire the API business of Raghava Life Sciences for up to ₹135 Crore, expanding its manufacturing capabilities.
RPG Life Sciences' subsidiary will acquire the API and intermediates business of Raghava Life Sciences for Rs. 135 Crore via a slump sale.
RPG Life Sciences reported robust Q1 FY27 results with 15.8% revenue growth and 17.0% PAT growth. Strategy focuses on building a specialty/chronic portfolio and expanding API and international footprint.
RPG Life Sciences Ltd reported revenue from operations of ₹195.7 Cr (+15.9% YoY) and net profit of ₹30.8 Cr (+17.1% YoY) for Q1 FY27.
RPG Life Sciences reports 8.3% YoY revenue growth to ₹707.5 cr in FY26, driven by domestic formulations outperforming the market by 1.6x.
RPG Life Sciences delivered strong Q4 FY26 performance with 23.6% revenue growth and 58.1% PAT growth (excl. exceptions), driven by Domestic Formulations and margin expansion.
RPG Life Sciences Ltd reported revenue from operations of ₹176.9 Cr (+23.6% YoY) and net profit of ₹29.9 Cr (-74.5% YoY) for Q4 FY26.